Less Than Lethal Act

WHAT HAPPENED: Senator Barrasso (R-WY) introduced S3514 on December 16, 2025. The bill was read twice and referred to the Senate Committee on Finance. A companion House bill (HR4242, the 'Innovate Less Lethal to De-Escalate Tax Modernization Act') has advanced further — placed on the Union Calendar (Calendar No. 407), meaning it has passed committee and is eligible for floor consideration. The Senate version remains in early stage with no committee markup scheduled. The bill would amend Section 4182 of the Internal Revenue Code to exempt devices that expel projectiles at ≤500 ft/s, cannot accept standard firearm ammunition, and cannot accept pistol-grip or semiautomatic-fed magazines.

THE MONEY TRAIL: This bill does NOT authorize or appropriate any spending. It is a tax expenditure — the government forgoes revenue from the existing federal excise tax on firearms and ammunition (currently 10% on pistols/revolvers, 11% on other firearms, 11% on ammunition). By exempting less-than-lethal devices, the bill reduces the tax burden on manufacturers like Axon. The eliminated tax liability flows directly to the manufacturer's bottom line as higher net revenue per unit, assuming pricing holds constant. If Axon passes savings to customers, lower prices could drive volume expansion in law enforcement and civilian markets. No new government funds are created — this is a tax reduction mechanism.

STRUCTURAL WINNERS: The primary beneficiary is Axon Enterprise ($AXON), as TASER devices are the dominant less-than-lethal projectile system in the US law enforcement market. The bill's technical definition (velocity ≤500 ft/s, no standard ammunition compatibility) maps precisely onto Axon's conducted energy weapon product line. No other publicly traded pure-play less-than-lethal manufacturer is directly named or implied in the legislation. Diversified defense contractors with non-lethal munitions programs could benefit secondarily, but their exposure is minimal relative to total revenue.

MARKET DATA CONTEXT: AXON currently trades at $393.3, near the lower end of its 52-week range ($339.01 — $885.92). The stock has declined 7.39% over the past 30 days and 0.96% over the past 7 days. The recent slide from the April 28 close of $406.31 to $393.3 represents a 3.2% two-day drop. This weakness may reflect broader market rotation or sector sentiment, but it sets a lower entry point ahead of a legislative catalyst that is not yet priced in. The bill's early legislative stage means it carries execution risk, but the companion House bill advancing past committee is a positive signal of bipartisan momentum on tax modernization for less-lethal devices.

TIMELINE AND REMAINING STEPS: For S3514 to become law: (a) Senate Finance Committee markup and vote, (b) Senate floor vote, (c) House passage (either HR4242 or similar language), (d) Presidential signature. The House version's placement on the Union Calendar is the more advanced action — if the House passes HR4242, the Senate could take it up directly or merge language into a tax extender package. Given the bill's modest scope and bipartisan appeal (tax relief for non-lethal law enforcement tools), a path through a year-end tax vehicle in the 119th Congress is plausible but not guaranteed. No committee hearings or markups have been scheduled for the Senate version as of April 30, 2026.